Skip to main content

Advertisement

SpringerLink
Log in

Comprehensive analysis of CDK5 as a novel biomarker for progression in esophageal cancer

  • Original Article
  • Published:
Esophagus Aims and scope Submit manuscript

Abstract

Background

Cyclin-dependent kinase 5 (CDK5) is a member of the cyclin-dependent kinase family, and unlike the rest of the members of the family, its kinase activity is independent of cyclins. Accumulating evidence has shown that CDK5 plays a significant role in the progress of tumorigenesis except in nervous system. In particular, the expression of CDK5 and its function in esophageal cancer (ESCA) remain unknown.

Methods

With TCGA and GEO databases, CDK5 was analyzed with the expression, predicted value, clinical relationship, functional enrichment, immune cell infiltration and immune molecules in ESCA. In addition, we explored the CDK5 expression with local datasets and the influence of CDK5 on proliferation, migration and invasion behaviors of the esophageal squamous cell carcinoma (ESCC) cells in vitro and in vivo experiments.

Results

CDK5 expression was upregulated in ESCA, and this regulation has been verified in cell lines of ESCC. Further analysis has found that the expression of CDK5 was correlated with race, weight, BMI, histological type and tumor central location in ESCA. KEGG analysis revealed that CDK5 was involved in the progress of cancers, innate immune system and PI3K-Akt signaling pathway. CDK5 was closely related to immune cells and immune molecules in ESCA. Functional experiments confirmed CDK5 was an oncogene in ESCC by in vivo and in vitro models.

Conclusions

This study shows that CDK5 is a risk factor to promote tumor progression, and Roscovitine could be one of the effective tools in the therapy of ESCA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability

The datasets acquired and analyzed in this study are available from the corresponding author.

References

  1. Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg. 2018;41:210–5.

    Article  PubMed  Google Scholar 

  2. Lin Y, Totsuka Y, He Y, et al. Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013;23:233–42.

    Article  PubMed  Google Scholar 

  3. Alsop BR, Sharma P. Esophageal Cancer. Gastroenterol Clin North Am. 2016;45:399–412.

    Article  PubMed  Google Scholar 

  4. Zheng C, Tang YD. The emerging roles of the CDK/cyclin complexes in antiviral innate immunity. J Med Virol. 2022;94:2384–7.

    Article  CAS  PubMed  Google Scholar 

  5. Wilkaniec A, Czapski GA, Adamczyk A. Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses. J Neurochem. 2016;136:222–33.

    Article  CAS  PubMed  Google Scholar 

  6. Gupta KK, Singh SK. Cdk5: A main culprit in neurodegeneration. Int J Neurosci. 2019;129:1192–7.

    Article  PubMed  Google Scholar 

  7. Zhou Y, Wang X, Lv P, Yu H, Jiang X. CDK5 Knockdown inhibits proliferation and induces apoptosis and Cell Cycle Arrest in Human Glioblastoma. J Cancer. 2021;12:3958–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sang Y, Li Y, Zhang Y, et al. CDK5-dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity. Nat Commun. 2019;10:4013.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Wang F, Zhao W, Gao Y, et al. CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis. J exper clin cancer res. 2019;38:286.

    Article  Google Scholar 

  10. Jin X, Yang C, Fan P, et al. CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion. J Biol Chem. 2017;292:6269–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49:D605-d612.

    Article  CAS  PubMed  Google Scholar 

  12. Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics (Oxford, England). 2019;35:4200–2.

    CAS  PubMed  Google Scholar 

  13. Chen YC, Hsieh HH, Chang HC, Wang HC, Lin WJ, Lin JJ. CDC25B induces cellular senescence and correlates with tumor suppression in a p53-dependent manner. J Biol Chem. 2021;296:100564.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lynch SM, McKenna MM, Walsh CP, McKenna DJ. miR-24 regulates CDKN1B/p27 expression in prostate cancer. Prostate. 2016;76:637–48.

    Article  CAS  PubMed  Google Scholar 

  15. Hu M, Gu J, Su W, et al. DNM1: a prognostic biomarker associated with immune infiltration in colon cancer-a study based on tcga database. Biomed Res Int. 2021;2021:4896106.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Donehower LA, Soussi T, Korkut A, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 2019;28:1370-1384.e1375.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Huang YF, Niu WB, Hu R, et al. FIBP knockdown attenuates growth and enhances chemotherapy in colorectal cancer via regulating GSK3β-related pathways. Oncogenesis. 2018;7:77.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Liu S, Wang H, Li J, et al. FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction. Cell Death Dis. 2020;11:804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wang SC. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014;35:178–86.

    Article  PubMed  Google Scholar 

  20. Mollica Poeta V, Massara M, Capucetti A, Bonecchi R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol. 2019;10:379.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Garrido F, Aptsiauri N. Cancer immune escape: MHC expression in primary tumours versus metastases. Immunology. 2019;158:255–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research was supported by grant from the National Natural Science Foundation of China (NO.81601043).

Author information

Author notes

  1. Rui Ling, Yucheng Sheng and Yuwen Hu have contributed equally to this paper.

Authors and Affiliations

  1. Department of Central Laboratory, Affiliated Hospital of Jiangsu University, 438 Jiefang Road, Zhenjiang, 212001, China

    Rui Ling, Yucheng Sheng, Yuwen Hu, Deqian Wang, Yuepeng Zhou & Yang Shu

Authors
  1. Rui Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yucheng Sheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuwen Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Deqian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuepeng Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yang Shu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RL and YS (Yucheng Sheng) completed the experiments. YH, YS (Yucheng Sheng), DW, YS (Yang Shu) analyzed the data. YZ and YS (Yang Shu) designed this work. YS (Yang Shu) wrote this manuscript. All the authors contributed to reading and  revising the manuscript.

Corresponding authors

Correspondence to Yuepeng Zhou or Yang Shu.

Ethics declarations

Ethical Statement

This study with human tissues was approved by the ethics committee of the Affiliated Hospital of Jiangsu University. The procedures with human tissues were performed as ethical standards of the ethics committee, the Helsinki Declaration of 1975 and its later amendments(ethical code:KY201902).

Conflict of interest

All the authors declare that there is no conflict of interest in this paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 2135 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ling, R., Sheng, Y., Hu, Y. et al. Comprehensive analysis of CDK5 as a novel biomarker for progression in esophageal cancer. Esophagus 20, 502–514 (2023). https://doi.org/10.1007/s10388-023-00988-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10388-023-00988-z

Keywords

Search

Navigation